Evidence
RNA Biol. 2024 Jan;21(1):1-15. doi: 10.1080/15476286.2023.2290769. Epub 2023 Dec 19.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD), which affects approximately 25% of the global population, is an urgent health issue leading to various metabolic comorbidities. Circular RNAs (circRNAs), covalently closed RNA molecules, are characterized by ubiquity, diversity, stability, and conservatism. Indeed, they participate in various biological processes via distinct mechanisms that could modify the natural history of NAFLD. In this review, we briefly introduce the biogenesis, characteristics, and biological functions of circRNAs. Furthermore, we summarize circRNAs expression profiles in NAFLD by intersecting seven sequencing data sets and describe the cellular roles of circRNAs and their potential advantages as biomarkers of NAFLD. In addition, we emphatically discuss the exosomal non-coding RNA sorting mechanisms and possible functions in recipient cells. Finally, we extensively discuss the potential application of targeting disease-related circRNAs and competing endogenous RNA networks through gain-of-function and loss-of-function approaches in targeted therapy of NAFLD.
PMID:38113132 | DOI:10.1080/15476286.2023.2290769
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
🌐 90 Days
VR Related Evidence Matrix
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Whole Transcriptome Sequencing of Peripheral Blood Identifies the Alzheimer's Disease-Related circRNA-miRNA-lncRNA Pathway
- Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes
- Emerging roles of RNA-binding proteins in fatty liver disease
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- The gut-liver axis in fatty liver disease: role played by natural products
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Noncoding RNA Lipotherapeutics: A Promising Breakthrough in Pulmonary Hypertension Treatment
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- Synthesis and biological evaluation of the novel chrysin prodrug for non-alcoholic fatty liver disease treatment
- Exploring Bile-Acid Changes and Microflora Profiles in Chicken Fatty Liver Disease Model
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases)
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Six-gene prognostic signature for non-alcoholic fatty liver disease susceptibility using machine learning
- From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients
- Mass spectrometry imaging-based metabolomics highlights spatial metabolic alterations in three types of liver injuries
- Awareness of Non-alcoholic Fatty Liver Disease and Its Determinants in Jazan, Saudi Arabia: A Cross-Sectional Study
- Occult liver disease: a multinational perspective
- Relation between non-alcoholic fatty liver disease and carotid artery intimal media thickness as a surrogate for atherosclerosis: a systematic review and meta-analysis
- The Global Epidemic of Metabolic Fatty Liver Disease
- Integrating network pharmacology and experimental validation reveals therapeutic effects of D-mannose on NAFLD through mTOR suppression
- Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease
- Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Correlation of Grades of Non-alcoholic Fatty Liver on Ultrasound With Blood Parameters
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- Integrative analysis identifies oxidative stress biomarkers in non-alcoholic fatty liver disease via machine learning and weighted gene co-expression network analysis
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Bacteroides and NAFLD: pathophysiology and therapy
- Screening the General Population for Non-Alcoholic Fatty Liver Disease: Model Development and Validation
- Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature
- Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study
- Genome-wide profiling of histone acetylation enhancer of fatty liver hemorrhagic syndrome in laying hens
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Targeting Non-Alcoholic Fatty Liver Disease with Hawthorn Ethanol Extract (HEE): A Comprehensive Examination of Hepatic Lipid Reduction and Gut Microbiota Modulation
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
Evidence Blueprint
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
🌐 365 Days
VR Related Evidence Matrix
- Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Identification and characterization of circular RNA in the model of autism spectrum disorder from PM2.5 exposure
- Whole Transcriptome Sequencing of Peripheral Blood Identifies the Alzheimer's Disease-Related circRNA-miRNA-lncRNA Pathway
- Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes
- Interaction between SIRT1 and non-coding RNAs in different disorders
- Emerging roles of RNA-binding proteins in fatty liver disease
- Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Metabolic dysfunction: The silenced connection with fatty liver disease
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Decoding m6A mRNA methylation by reader proteins in liver diseases
- Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
- Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- The gut-liver axis in fatty liver disease: role played by natural products
- Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- The levels of IL1RN is a factor influencing the onset of rheumatoid arthritis in non-alcoholic fatty liver disease
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications
- Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases
- N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment
- Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Alternative splicing: a bridge connecting NAFLD and HCC
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Adverse Maternal Environments Perturb Hepatic DNA Methylome and Transcriptome Prior to the Adult-Onset Non-Alcoholic Fatty Liver Disease in Mouse Offspring
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance
- The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era?
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- lncRNA and circRNA expression profiles in the hippocampus of Aβ25‑35‑induced AD mice treated with Tripterygium glycoside
- Regulation of neuronal circHomer1 biogenesis by PKA/CREB/ERK-mediated pathways and effects of glutamate and dopamine receptor blockade
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Beyond ribosome biogenesis: noncoding nucleolar RNAs in physiology and tumor biology
- Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced Non-alcoholic Fatty Liver Disease in rats
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- Histone Methylation Regulation as a Potential Target for Non-alcoholic Fatty Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- The Correlation Between Serum Copper and Non-alcoholic Fatty Liver Disease in American Adults: an Analysis Based on NHANES 2011 to 2016
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Gut Microbiota in Patients with Non-Alcoholic Fatty Liver Disease without Type 2 Diabetes: Stratified by Body Mass Index
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications